FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2587586062> ?p ?o ?g. }

• W2587586062 abstract "Abstract Abstract 2178 The major therapeutic barrier in acute myeloid leukemia is chemotherapy resistance. Although most patients will respond to treatment with chemotherapy over 50% of responders will relapse and eventually die of disease. Many hypotheses have been proposed to explain chemotherapy resistance but none of these have lead to new therapies or a complete understanding of the molecular mechanisms of AML chemotherapy resistance. In order to develop an improved understanding of chemotherapy resistance in AML, we have developed a chemotherapy model of human AML in NSG mice. Mice are engrafted with primary AML samples from patients seen at diagnosis or relapse of disease or who demonstrated primary chemotherapy resistance. After demonstrating AML engraftment, mice are treated with cytosine arabinoside (Ara-C) given IP daily for 5 days as a single agent at 10mg/kg daily, 30mg/kg daily, and 60 mg/kg daily which correlates with human dosing. In >75% of mice treated with 10 mg/kg of Ara-C there is a cytoreductive effect at 2 weeks post-treatment with relapse at 4 weeks post-treatment. In all mice treated with 30 mg/kg of Ara-C there was a cytoreductive effect at 2 weeks post-treatment with relapse at 4 weeks post-treatment. In all mice treated with 60 mg/kg of Ara-C there was a cytoreductive effect at 2 weeks post-treatment with relapse 4–13 weeks post-treatment when relapse occurred, demonstrating that there is a dose response relationship in the model in terms of nadir leukemic burden and time to peripheral blood relapse. Two weeks after treatment, there was up to a 50-fold decrease in total AML cell burden in the peripheral blood of mice treated with 30 mg/kg and and up to a 70-fold decrease in the peripheral blood of mice treated with 60 mg/kg of Ara-C. We found no enhancement in quiescent or G0 cells after chemotherapy treatment. We did however, in 1/5 samples tested see a change in phenotype after chemotherapy treatment with an increase in the total number of CD34+38+ cells with a concomitant decrease in CD34-38+ cells. In all other samples tested, there was no change in phenotype after chemotherapy treatment. These results are in contrast to recent studies using a 1 gm/kg dose of Ara-C and analysis at Day 3 following a single treatment. These results have implications for understanding the physiologic response to Ara-C at different doses. We are currently analyzing mRNA expression arrays of AML without or with Ara-C treatment to identify novel mechanisms of chemotherapy resistance. Taken together, this model provides a novel approach for development of new therapies in AML. Disclosures: Carroll: Sanofi Aventis Corporation: Research Funding; Kyowa Hakko Kirin Pharmaceuticals: Research Funding; Agios Pharmaceuticals: Research Funding." @default.
• W2587586062 created "2017-02-17" @default.
• W2587586062 creator A5024399341 @default.
• W2587586062 creator A5032477226 @default.
• W2587586062 creator A5035410041 @default.
• W2587586062 creator A5053533004 @default.
• W2587586062 date "2010-11-19" @default.
• W2587586062 modified "2023-10-01" @default.
• W2587586062 title "Ara-C Treatment of Acute Myeloid Leukemia Does Not Lead to Prolonged Enrichment of Stem Cells or a Cell Cycle Arrest" @default.
• W2587586062 doi "https://doi.org/10.1182/blood.v116.21.2178.2178" @default.
• W2587586062 hasPublicationYear "2010" @default.
• W2587586062 type Work @default.
• W2587586062 sameAs 2587586062 @default.
• W2587586062 citedByCount "0" @default.
• W2587586062 crossrefType "journal-article" @default.
• W2587586062 hasAuthorship W2587586062A5024399341 @default.
• W2587586062 hasAuthorship W2587586062A5032477226 @default.
• W2587586062 hasAuthorship W2587586062A5035410041 @default.
• W2587586062 hasAuthorship W2587586062A5053533004 @default.
• W2587586062 hasConcept C104317684 @default.
• W2587586062 hasConcept C126322002 @default.
• W2587586062 hasConcept C143998085 @default.
• W2587586062 hasConcept C150194340 @default.
• W2587586062 hasConcept C190727270 @default.
• W2587586062 hasConcept C203014093 @default.
• W2587586062 hasConcept C2776239401 @default.
• W2587586062 hasConcept C2776694085 @default.
• W2587586062 hasConcept C2777288759 @default.
• W2587586062 hasConcept C2778041864 @default.
• W2587586062 hasConcept C2778461978 @default.
• W2587586062 hasConcept C2778729363 @default.
• W2587586062 hasConcept C2779282312 @default.
• W2587586062 hasConcept C28328180 @default.
• W2587586062 hasConcept C54355233 @default.
• W2587586062 hasConcept C55493867 @default.
• W2587586062 hasConcept C71924100 @default.
• W2587586062 hasConcept C86803240 @default.
• W2587586062 hasConcept C90924648 @default.
• W2587586062 hasConcept C98274493 @default.
• W2587586062 hasConceptScore W2587586062C104317684 @default.
• W2587586062 hasConceptScore W2587586062C126322002 @default.
• W2587586062 hasConceptScore W2587586062C143998085 @default.
• W2587586062 hasConceptScore W2587586062C150194340 @default.
• W2587586062 hasConceptScore W2587586062C190727270 @default.
• W2587586062 hasConceptScore W2587586062C203014093 @default.
• W2587586062 hasConceptScore W2587586062C2776239401 @default.
• W2587586062 hasConceptScore W2587586062C2776694085 @default.
• W2587586062 hasConceptScore W2587586062C2777288759 @default.
• W2587586062 hasConceptScore W2587586062C2778041864 @default.
• W2587586062 hasConceptScore W2587586062C2778461978 @default.
• W2587586062 hasConceptScore W2587586062C2778729363 @default.
• W2587586062 hasConceptScore W2587586062C2779282312 @default.
• W2587586062 hasConceptScore W2587586062C28328180 @default.
• W2587586062 hasConceptScore W2587586062C54355233 @default.
• W2587586062 hasConceptScore W2587586062C55493867 @default.
• W2587586062 hasConceptScore W2587586062C71924100 @default.
• W2587586062 hasConceptScore W2587586062C86803240 @default.
• W2587586062 hasConceptScore W2587586062C90924648 @default.
• W2587586062 hasConceptScore W2587586062C98274493 @default.
• W2587586062 hasLocation W25875860621 @default.
• W2587586062 hasOpenAccess W2587586062 @default.
• W2587586062 hasPrimaryLocation W25875860621 @default.
• W2587586062 hasRelatedWork W132959109 @default.
• W2587586062 hasRelatedWork W156717385 @default.
• W2587586062 hasRelatedWork W1602123006 @default.
• W2587586062 hasRelatedWork W2057484677 @default.
• W2587586062 hasRelatedWork W2062808248 @default.
• W2587586062 hasRelatedWork W2088569618 @default.
• W2587586062 hasRelatedWork W2143244096 @default.
• W2587586062 hasRelatedWork W2467004252 @default.
• W2587586062 hasRelatedWork W2476155284 @default.
• W2587586062 hasRelatedWork W2530236591 @default.
• W2587586062 hasRelatedWork W2531690562 @default.
• W2587586062 hasRelatedWork W2532111429 @default.
• W2587586062 hasRelatedWork W2535637335 @default.
• W2587586062 hasRelatedWork W2550175900 @default.
• W2587586062 hasRelatedWork W2553566409 @default.
• W2587586062 hasRelatedWork W2576736597 @default.
• W2587586062 hasRelatedWork W2590160476 @default.
• W2587586062 hasRelatedWork W2979325698 @default.
• W2587586062 hasRelatedWork W2980047921 @default.
• W2587586062 hasRelatedWork W3097947601 @default.
• W2587586062 isParatext "false" @default.
• W2587586062 isRetracted "false" @default.
• W2587586062 magId "2587586062" @default.
• W2587586062 workType "article" @default.